• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age

    Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age

  2. Research and Markets: Australia Orthopedic Devices Market Assessment and Forecasts To 2020

    Research and Markets: Australia Orthopedic Devices Market Assessment and Forecasts To 2020

  3. Research and Markets: Canada Orthopedic and Spine Market - Forecast and Trends Through 2019

    Research and Markets: Canada Orthopedic and Spine Market - Forecast and Trends Through 2019

  4. Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy

    Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy

  5. Veracyte, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results, Provides 2015 Financial Outlook

    Veracyte, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results, Provides 2015 Financial Outlook

  6. The Global Gaucher Disease Market Will Exhibit Moderate Growth from 2014 to 2019: TechNavio

    The Global Gaucher Disease Market Will Exhibit Moderate Growth from 2014 to 2019: TechNavio

  7. Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an ...

    Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC

  8. Aura Biosciences Closes $21M Series B Financing

    Aura Biosciences Closes $21M Series B Financing

  9. Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

    Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluentâ„¢ (alirocumab) Published in The New England Journal of Medicine

  10. Research and Markets: European Cystic Fibrosis Market 2015-2019 - Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals

    Research and Markets: European Cystic Fibrosis Market 2015-2019 - Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.